Key facts for NCD 190.32
- Benefit category
- Diagnostic Laboratory Tests
- Effective date
- 11/25/2002
- Implemented 01/01/2003
- Transmittal
- Transmittal 17
- Versions published
- 1
- Lab edit list
- 3,933 covered ICD-10
- 233 non-covered
TL;DR
NCD 190.32 sets Medicare's national policy for gamma glutamyl transferase under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. • To provide information about known or suspected hepatobiliary disease, for example: As a laboratory NCD it carries a national ICD-10 edit list: 3,933 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.
Item or service described
Gamma Glutamyl Transferase (GGT) is an intracellular enzyme that appears in blood following leakage from cells. Renal tubules, liver, and pancreas contain high amounts, although the measurement of GGT in serum is almost always used for assessment of hepatobiliary function. Unlike other enzymes which are found in heart, skeletal muscle, and intestinal mucosa as well as liver, the appearance of an elevated level of GGT in serum is almost always the result of liver disease or injury. It is specifically useful to differentiate elevated alkaline phosphatase levels when the source of the alkaline phosphatase increase (bone, liver, or placenta) is unclear. The combination of high alkaline phosphatase and a normal GGT does not, however, rule out liver disease completely.
As well as being a very specific marker of hepatobiliary function, GGT is also a very sensitive marker for hepatocellular damage. Abnormal concentrations typically appear before elevations of other liver enzymes or bilirubin are evident. Obstruction of the biliary tract, viral infection (e.g., hepatitis, mononucleosis), metastatic cancer, exposure to hepatotoxins (e.g., organic solvents, drugs, alcohol), and use of drugs that induce microsomal enzymes in the liver (e.g., cimetidine, barbiturates, phenytoin, and carbamazepine) all can cause a moderate to marked increase in GGT serum concentration. In addition, some drugs can cause or exacerbate liver dysfunction (e.g., atorvastatin, troglitazone, and others as noted in FDA Contraindications and Warnings.)
GGT is useful for diagnosis of liver disease or injury, exclusion of hepatobiliary involvement related to other diseases, and patient management during the resolution of existing disease or following injury.
Indications and limitations of coverage
Indications
• To provide information about known or suspected hepatobiliary disease, for example:
• Following chronic alcohol or drug ingestion.
• Following exposure to hepatotoxins.
• When using medication known to have a potential for causing liver toxicity (e.g., following the drug manufacturer's recommendations).
• Following infection (e.g., viral hepatitis and other specific infections such as amoebiasis, tuberculosis, psittacosis, and similar infections).
• To assess liver injury/function following diagnosis of primary or secondary malignant neoplasms.
• To assess liver injury/function in a wide variety of disorders and diseases known to cause liver involvement (e.g., diabetes mellitus, malnutrition, disorders of iron and mineral metabolism, sarcoidosis, amyloidosis, lupus, and hypertension).
• To assess liver function related to gastrointestinal disease.
• To assess liver function related to pancreatic disease.
• To assess liver function in patients subsequent to liver transplantation.
• To differentiate between the different sources of elevated alkaline phosphatase activity.
Limitations
When used to assess liver dysfunction secondary to existing non-hepatobiliary disease with no change in signs, symptoms, or treatment, it is generally not necessary to repeat a GGT determination after a normal result has been obtained unless new indications are present.
If the GGT is the only "liver" enzyme abnormally high, it is generally not necessary to pursue further evaluation for liver disease for this specific indication.
When used to determine if other abnormal enzyme tests reflect liver abnormality rather than other tissue, it generally is not necessary to repeat a GGT more than one time per week.
Because of the extreme sensitivity of GGT as a marker for cytochrome oxidase induction or cell membrane permeability, it is generally not useful in monitoring patients with known liver disease.
Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).
Text reproduced from the CMS Medicare Coverage Database record for NCD 190.32 version 1. View the original on cms.gov.
Laboratory NCD code lists (October 2026)
Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 3,933 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.
1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.
| Code | Code set |
|---|---|
| 82977 | CPT (descriptor licensed by AMA) |
What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $7.20, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.
| Code | CLFS amount | With QW | Pricing |
|---|---|---|---|
| 82977 | $7.20 | $7.20 | national payment amount |
The first 40 of 3,933 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.
| ICD-10-CM | Description | Effective |
|---|---|---|
| A02.1 | Salmonella sepsis | 2015-10-01 |
| A06.0 | Acute amebic dysentery | 2015-10-01 |
| A06.1 | Chronic intestinal amebiasis | 2015-10-01 |
| A06.2 | Amebic nondysenteric colitis | 2015-10-01 |
| A06.3 | Ameboma of intestine | 2015-10-01 |
| A06.4 | Amebic liver abscess | 2015-10-01 |
| A06.5 | Amebic lung abscess | 2015-10-01 |
| A06.6 | Amebic brain abscess | 2015-10-01 |
| A06.7 | Cutaneous amebiasis | 2015-10-01 |
| A06.81 | Amebic cystitis | 2015-10-01 |
| A06.82 | Other amebic genitourinary infections | 2015-10-01 |
| A06.89 | Other amebic infections | 2015-10-01 |
| A06.9 | Amebiasis, unspecified | 2015-10-01 |
| A17.83 | Tuberculous neuritis | 2015-10-01 |
| A17.9 | Tuberculosis of nervous system, unspecified | 2015-10-01 |
| A18.31 | Tuberculous peritonitis | 2015-10-01 |
| A18.32 | Tuberculous enteritis | 2015-10-01 |
| A18.39 | Retroperitoneal tuberculosis | 2015-10-01 |
| A18.82 | Tuberculosis of other endocrine glands | 2015-10-01 |
| A18.83 | Tuberculosis of digestive tract organs, not elsewhere classified | 2015-10-01 |
| A18.84 | Tuberculosis of heart | 2015-10-01 |
| A18.89 | Tuberculosis of other sites | 2015-10-01 |
| A19.9 | Miliary tuberculosis, unspecified | 2015-10-01 |
| A20.0 | Bubonic plague | 2015-10-01 |
| A20.1 | Cellulocutaneous plague | 2015-10-01 |
| A20.2 | Pneumonic plague | 2015-10-01 |
| A20.3 | Plague meningitis | 2015-10-01 |
| A20.7 | Septicemic plague | 2015-10-01 |
| A20.8 | Other forms of plague | 2015-10-01 |
| A20.9 | Plague, unspecified | 2015-10-01 |
| A22.7 | Anthrax sepsis | 2015-10-01 |
| A26.0 | Cutaneous erysipeloid | 2015-10-01 |
| A26.7 | Erysipelothrix sepsis | 2015-10-01 |
| A26.8 | Other forms of erysipeloid | 2015-10-01 |
| A26.9 | Erysipeloid, unspecified | 2015-10-01 |
| A27.0 | Leptospirosis icterohemorrhagica | 2015-10-01 |
| A30.1 | Tuberculoid leprosy | 2015-10-01 |
| A32.0 | Cutaneous listeriosis | 2015-10-01 |
| A32.11 | Listerial meningitis | 2015-10-01 |
| A32.12 | Listerial meningoencephalitis | 2015-10-01 |
233 diagnosis codes deny automatically under this NCD; the first 20 are shown.
| ICD-10-CM | Description |
|---|---|
| R99 | Ill-defined and unknown cause of mortality |
| Z00.00 | Encounter for general adult medical examination without abnormal findings |
| Z00.01 | Encounter for general adult medical examination with abnormal findings |
| Z00.110 | Health examination for newborn under 8 days old |
| Z00.111 | Health examination for newborn 8 to 28 days old |
| Z00.121 | Encounter for routine child health examination with abnormal findings |
| Z00.129 | Encounter for routine child health examination without abnormal findings |
| Z00.5 | Encounter for examination of potential donor of organ and tissue |
| Z00.6 | Encounter for examination for normal comparison and control in clinical research program |
| Z00.70 | Encounter for examination for period of delayed growth in childhood without abnormal findings |
| Z00.71 | Encounter for examination for period of delayed growth in childhood with abnormal findings |
| Z00.8 | Encounter for other general examination |
| Z02.0 | Encounter for examination for admission to educational institution |
| Z02.1 | Encounter for pre-employment examination |
| Z02.2 | Encounter for examination for admission to residential institution |
| Z02.3 | Encounter for examination for recruitment to armed forces |
| Z02.4 | Encounter for examination for driving license |
| Z02.5 | Encounter for examination for participation in sport |
| Z02.6 | Encounter for examination for insurance purposes |
| Z02.71 | Encounter for disability determination |
Changed in October 2026
The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 0 codes added and 4 codes removed against January 2026. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.
| ICD-10-CM | Description | Was | Why |
|---|---|---|---|
| T52.8X1A | Toxic effect of other organic solvents, accidental (unintentional), initial encounter | covered | deleted from ICD-10-CM; replaced by T52.811A, T52.821A, T52.891A |
| T52.8X2A | Toxic effect of other organic solvents, intentional self-harm, initial encounter | covered | deleted from ICD-10-CM; replaced by T52.812A, T52.822A, T52.892A |
| T52.8X3A | Toxic effect of other organic solvents, assault, initial encounter | covered | deleted from ICD-10-CM; replaced by T52.813A, T52.823A, T52.893A |
| T52.8X4A | Toxic effect of other organic solvents, undetermined, initial encounter | covered | deleted from ICD-10-CM; replaced by T52.814A, T52.824A, T52.894A |
Codes on this NCD's list by release: October 2025: 4,141 · January 2026: 4,170 · October 2026: 4,166. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.
Revision history
07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)
07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 190.32
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 190.32
What does NCD 190.32 cover?
• To provide information about known or suspected hepatobiliary disease, for example: The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 190.32 take effect?
The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.
Does a Local Coverage Determination override NCD 190.32?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Which diagnosis codes are covered under NCD 190.32?
The October 2026 laboratory NCD edit list contains 3,933 ICD-10-CM codes that support gamma glutamyl transferase (for example A02.1 Salmonella sepsis; A06.0 Acute amebic dysentery; A06.1 Chronic intestinal amebiasis) and 233 codes that deny. The list applies to 82977.
How often does the lab NCD code list for 190.32 change?
CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.
CMS guidance
Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:
- Complying With Documentation Requirements for Lab Services(MLN909221, )What documentation supports a laboratory claim: the order, the medical necessity and the results.
- Clinical Laboratory Fee Schedule(MLN006818, )How the Clinical Laboratory Fee Schedule is set, including data reporting and the payment determination.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Laboratory NCD ICD-10 code lists, October 2026Version October 2026 · effective 2026-10-01 · file 2026400-Initial-ICD10-NCD-Spreadsheet-20260601-508.xlsxSHA-256 ec4361dc65f63432…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.